Sweden · Delayed Price · Currency is SEK EQL Pharma AB Earnings Call Transcripts
Fiscal Year 2026
-
Record quarterly sales and margin recovery driven by strong UK and German product performance, despite ongoing supply chain challenges. Full-year growth guidance remains at 15% with major launches and operational improvements expected to drive future growth.
-
Q2 saw minimal sales growth and a sharp drop in margins due to supply disruptions, with key product launches delayed. Management is implementing new systems and processes to address operational challenges and expects gradual recovery, targeting 15% sales growth and 20% EBITDA margin for the year.
-
Q1 delivered 30% sales growth and a 24% EBITDA margin, with strong EBIT and a robust product pipeline. Expansion into Germany and the Netherlands, ongoing Medilink integration, and a focus on Special Generics support long-term growth ambitions.
Fiscal Year 2025
-
Q4 saw 45% sales growth and a 25% EBITDA margin, completing the five-year plan. The company expanded its product pipeline, entered the GCC market, and raised SEK 350 million for the Medilink acquisition, with a focus on managing leverage and sustaining growth.
-
A new five-year plan targets 30% annual sales growth and an EBITDA margin above 25%, driven by organic pipeline launches, branded product expansion, specialty generics, and selective M&A. The business model remains asset-light, with a focus on operational efficiency and sustainability, while recent acquisitions like Medilink support both margin and geographic growth.
Fiscal Year 2024
-
Sales volumes for key products are stable, with new launches in Denmark expected to boost future sales. International expansion is progressing, though slowly, and the pipeline has grown with four new products. Gross margin has recovered and is expected to remain stable in the near term.